{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:39:58Z","timestamp":1790786398840,"version":"4.1.0"},"reference-count":96,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This MiniReview reports the current knowledge about the treatment of arterial hypertension with the third\u2010generation beta\u2010adrenoceptor antagonist (BAA) nebivolol. Furthermore, it reviews the advantages of nebivolol compared to the earlier generation of BAAs with respect to their different pharmacological properties. Beta\u2010adrenoceptor antagonists are a class of drugs applied for several different conditions, including hypertension and heart failure. They differ significantly in their pharmacological properties, including varying \u03b2<jats:sub>1<\/jats:sub>\/\u03b2<jats:sub>2<\/jats:sub>\u2010selectivity and\/or exertion of additive effects on the heart and circulation. Although these drugs have been a part of hypertensive therapy for about 40\u00a0years, the outcome of large clinical trials has put the role of BAAs into question. However, most of these results were based on first\u2010 and second\u2010generation BAAs and cannot be translated directly into third\u2010generation drugs. The third\u2010generation BAA nebivolol has the highest \u03b2<jats:sub>1<\/jats:sub>\u2010selectivity seen so far, together with additional vasodilating and anti\u2010oxidative properties. It is currently applied in the treatment of hypertension and congestive heart failure. Nebivolol has a unique pharmacological profile, despite showing similar blood pressure\u2010lowering effects, and has certain advantages in the treatment of hypertension compared to the previous generations of BAAs. This includes significant improvements in endothelial dysfunction, central haemodynamics and the degree of erectile dysfunction in men, a neutral\/beneficial metabolic profile and lastly a more favourable side effect profile. It is widely beneficial for, for example, sexually active men and patients with comorbidities such as type II diabetes mellitus, metabolic syndrome and chronic obstructive lung disorders. Whether the advantages translate to an improved long\u2010term clinical outcome remains to be clarified, and ongoing prospective studies will show this in the future.<\/jats:p>","DOI":"10.1111\/bcpt.13248","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T14:53:53Z","timestamp":1557327233000},"page":"189-201","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Nebivolol in the treatment of arterial hypertension"],"prefix":"10.1111","volume":"125","author":[{"given":"Nasima","family":"Olawi","sequence":"first","affiliation":[{"name":"Department of Biomedicine, Pharmacology Aarhus University Aarhus C Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Kr\u00fcger","sequence":"additional","affiliation":[{"name":"Clinic for Plastic, Aesthetic and Hand Surgery Otto von Guericke University Magdeburg Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Grimm","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Pharmacology Aarhus University Aarhus C Denmark"},{"name":"Clinic for Plastic, Aesthetic and Hand Surgery Otto von Guericke University Magdeburg Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Infanger","sequence":"additional","affiliation":[{"name":"Clinic for Plastic, Aesthetic and Hand Surgery Otto von Guericke University Magdeburg Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wehland","sequence":"additional","affiliation":[{"name":"Clinic for Plastic, Aesthetic and Hand Surgery Otto von Guericke University Magdeburg Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2016.00003"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2011.02.010"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67185-1"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.595496"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67573-3"},{"key":"e_1_2_7_9_1","first-page":"Cd002003","article-title":"Beta\u2010blockers for hypertension","volume":"1","author":"Wiysonge CS","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_10_1","first-page":"Cd001841","article-title":"First\u2010line drugs for hypertension","volume":"4","author":"Wright JM","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.208041"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000102042.83024.CA"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2016.10.005"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016112799959323"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.03.007"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-017-0716-3"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0435-5"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.5530\/jyp.2018.10.34"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartasia-2015-010656"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12396"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2010.00144"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/AC.65.5.2056244"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957040-00011"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026180325278"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03258273"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000571"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/08038020310023271"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000571"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199306000-00002"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02796.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2012.00911.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fjc.0000238593.67191.e2"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753944709104496"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04116"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04342.x"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000024"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000444"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2015.09.002"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2015.02.008"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-015-0596-3"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-010-0150-2"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc3001.094207"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-009-1170-1"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2009.00198.x"},{"key":"e_1_2_7_45_1","first-page":"371","article-title":"Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X","volume":"9","author":"Sen N","year":"2009","journal-title":"Anadolu Kardiyol Derg"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31815f5aeb"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.05.031"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.03.070"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.03.031"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283220ea4"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.089078"},{"key":"e_1_2_7_52_1","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/HJH.0b013e3283481a32","article-title":"Isolated systolic hypertension of young\u2010to\u2010middle\u2010age individuals implies a relatively low risk of developing hypertension needing treatment when central blood pressure is low","volume":"29","author":"Saladini F","year":"2011","journal-title":"J Hypertens"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000379702.37641.79"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2003.09.012"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.133801"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04342.x"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2017.26"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.155507"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3282f283c9"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBP.0b013e32833c8a64"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.96349"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.04.030"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60108-1"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.18.2227"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200727120-00006"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3181eb4ff2"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.6.4.471"},{"key":"e_1_2_7_68_1","first-page":"Hc01\u20104","article-title":"Beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension","volume":"8","author":"Bhosale VV","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200808010-00005"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00051145"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00237.2016"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.5761\/atcs.oa.16-00242"},{"key":"e_1_2_7_73_1","first-page":"131","article-title":"Nebivolol compared with metoprolol for erectile function in males undergoing coronary artery bypass graft","volume":"16","author":"Aldemir M","year":"2016","journal-title":"Anatol J Cardiol"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287216685027"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi115"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2005.03.733"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000392"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2016.11.007"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199502000-00012"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:CARD.0000029031.87129.05"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007437"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12745"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-017-0019-9"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0427-1"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2017.53.1.2560078"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001412"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.06979"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.5530\/jcdr.2017.2.10"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200112000-00014"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.303290"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2015.03.008"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248416644987"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.2006.2.3.303"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-018-0117-y"},{"key":"e_1_2_7_95_1","volume-title":"Basal Og Klinisk Farmakologi","author":"Br\u00f8sen K","year":"2014"},{"key":"e_1_2_7_96_1","unstructured":"USA F\u2010tfada.Nebivolol (Bystolic) 2007[updated 2007; cited]; Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021742s013lbl.pdf last accessed 31.4.2019. Accessed April 31 2019."},{"key":"e_1_2_7_97_1","unstructured":"USA F\u2010tfada.Propanolol (inderal). [cited]; Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/016418s080 016762s017 017683s008lbl.pdf last accessed 31.4.2019. Accessed April 31 2019."}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.13248","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13248","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.13248","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T22:25:02Z","timestamp":1694211902000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,4]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/bcpt.13248"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13248","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,4]]},"assertion":[{"value":"2019-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}